Stadler WM - Search Results

1

Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.

Lee RT, Kwon N, Wu J, To C, To S, Szmulewitz R, Tchekmedyian R, Holmes HM, Olopade OI, Stadler WM, Von Roenn J. Lee RT, et al. Among authors: stadler wm. Cancer. 2021 Jun 1;127(11):1827-1835. doi: 10.1002/cncr.33324. Epub 2021 Feb 1. Cancer. 2021. PMID: 33524183 Free article.

2

Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer.

Stadler WM, Sherman J, Bohlander SK, Roulston D, Dreyling M, Rukstalis D, Olopade OI. Stadler WM, et al. Cancer Res. 1994 Apr 15;54(8):2060-3. Cancer Res. 1994. PMID: 7513608

3

Increased p16 levels correlate with pRb alterations in human urothelial cells.

Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Yeager T, et al. Cancer Res. 1995 Feb 1;55(3):493-7. Cancer Res. 1995. PMID: 7834615

4

The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Stadler WM, Olopade OI. Stadler WM, et al. Urol Res. 1996;24(4):239-44. doi: 10.1007/BF00295899. Urol Res. 1996. PMID: 8873383

5

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.

Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Rini BI, et al. Among authors: stadler wm. Cancer. 1998 Apr 1;82(7):1352-8. doi: 10.1002/(sici)1097-0142(19980401)82:7<1352::aid-cncr19>3.0.co;2-5. Cancer. 1998. PMID: 9529028 Clinical Trial.

6

Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases.

Chekmareva MA, Kadkhodaian MM, Hollowell CM, Kim H, Yoshida BA, Luu HH, Stadler WM, Rinker-Schaeffer CW. Chekmareva MA, et al. Among authors: stadler wm. Cancer Res. 1998 Nov 1;58(21):4963-9. Cancer Res. 1998. PMID: 9810006

7

Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.

Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM. Ryan CW, et al. Among authors: stadler wm. Cancer. 2000 Mar 15;88(6):1317-24. Cancer. 2000. PMID: 10717612 Clinical Trial.

8

Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization.

Stadler WM, Steinberg G, Yang X, Hagos F, Turner C, Olopade OI. Stadler WM, et al. Clin Cancer Res. 2001 Jun;7(6):1676-82. Clin Cancer Res. 2001. PMID: 11410506

9

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.

Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Mani S, et al. Among authors: stadler wm. Cancer. 2001 Sep 15;92(6):1567-76. doi: 10.1002/1097-0142(20010915)92:6<1567::aid-cncr1483>3.0.co;2-l. Cancer. 2001. PMID: 11745236 Clinical Trial.

10

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.

Ryan CW, Vogelzang NJ, Stadler WM. Ryan CW, et al. Among authors: stadler wm. Cancer. 2002 May 15;94(10):2602-9. doi: 10.1002/cncr.10528. Cancer. 2002. PMID: 12173327 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

338 results

Search Page